Efficacy of Topical Cannabidiol for Eczema

Inclusion criteria

• All participants must be aged 25 years or older.
• Patients must be diagnosed with eczema, including atopic dermatitis, nummular eczema, lichen simplex chronicus, or prurigo nodularis, with pruritus persisting for more than 6 weeks.
• Patients must be willing to refrain from using other topical products throughout the 4-week study period.
• Patients must provide written informed consent to participate in the study.

Exclusion criteria

• Patients who have taken oral steroids, immunosuppressive drugs, or received phototherapy within the past 3 months.
• Patients with chronic kidney disease, liver cirrhosis, cancer, or thyroid disease.
• Pregnant or breastfeeding women, or women planning to become pregnant.
• Patients who develop erythematous itchy rash in response to an open patch test using cannabis extract products.
• Patients with a known allergy to cannabis-derived products, which may result from other ingredients and/or solvents used in the extraction process.
• Patients with severe or unstable cardio-pulmonary diseases (e.g., angina, peripheral vascular disease, cerebrovascular disease, or arrhythmia), or those at risk of cardiovascular disease.
• Patients with a history of psychosis, current active mood disorder, or anxiety disorder.
• Patients who are addicted to substances, including nicotine, or are heavy alcohol users.
• Patients using other medications, particularly opioids or sedatives such as benzodiazepines.
• Patients taking medications known to potentially interact with cannabis extracts, such as warfarin, fluoroquinolones, or dihydropyridine calcium channel blockers.